Literature DB >> 7589851

Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I.

D A D'Alessio1, R L Prigeon, J W Ensinck.   

Abstract

Glucagon-like peptide I (GLP-I)(7-36) amide is secreted by intestinal L-cells in response to food ingestion. GLP-I is a potent insulin secretagogue and also inhibits glucagon release. In addition, when given to humans in pharmacological amounts, GLP-I increases glucose disposal independent of its effects on islet hormone secretion. To test the hypothesis that this extrapancreatic effect of GLP-I on glucose disposition is present at physiological levels of GLP-I, we performed intravenous glucose tolerance tests (IVGTTs) 1 h after the following interventions: 1) the ingestion of 50 g fat to stimulate GLP-I secretion or the ingestion of water as a control and 2) infusion of GLP-I to attain physiological levels or a control infusion of saline. The results of the IVGTTs were analyzed using the minimal model technique to determine the insulin sensitivity index (SI) and indexes of insulin-independent glucose disposition, glucose effectiveness at basal insulin (SG), and glucose effectiveness at zero insulin (GEZI), as well as the glucose disappearance constant (k(g)) and the acute insulin response to glucose (AIRg). These parameters were compared between conditions of elevated circulating GLP-I and control conditions. After ingestion of fat and infusion of synthetic hormone, plasma GLP-I increased to similar levels; GLP-I did not change with water ingestion or saline infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589851     DOI: 10.2337/diab.44.12.1433

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  31 in total

Review 1.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  The vagus nerve, food intake and obesity.

Authors:  Hans-Rudolf Berthoud
Journal:  Regul Pept       Date:  2008-03-25

3.  Contributions of fat and protein to the incretin effect of a mixed meal.

Authors:  Guillaume Carrel; Léonie Egli; Christel Tran; Philippe Schneiter; Vittorio Giusti; David D'Alessio; Luc Tappy
Journal:  Am J Clin Nutr       Date:  2011-08-17       Impact factor: 7.045

4.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

Review 5.  Mechanistic systems modeling to guide drug discovery and development.

Authors:  Brian J Schmidt; Jason A Papin; Cynthia J Musante
Journal:  Drug Discov Today       Date:  2012-09-19       Impact factor: 7.851

Review 6.  Gut feelings about diabetes.

Authors:  Blandine Laferrère
Journal:  Endocrinol Nutr       Date:  2012-03-03

7.  Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance.

Authors:  Julio E Ayala; Deanna P Bracy; Freyja D James; Melissa A Burmeister; David H Wasserman; Daniel J Drucker
Journal:  Endocrinology       Date:  2010-08-04       Impact factor: 4.736

8.  The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

Authors:  Yan-Ling He; Brian M Sadler; Ron Sabo; Sebastien Balez; Yibin Wang; Joelle Campestrini; Aziz Laurent; Monica Ligueros-Saylan; Dan Howard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes.

Authors:  Hong Gao; Xinjun Wang; Zhiguo Zhang; Yisheng Yang; Jun Yang; Xiaoying Li; Guang Ning
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

10.  Effects of Diet on Bile Acid Metabolism and Insulin Resistance in Type 2 Diabetic Rats after Roux-en-Y Gastric Bypass.

Authors:  Cheng-Xiang Shan; Nian-Cun Qiu; Miao-E Liu; Si-Luo Zha; Xin Song; Zhi-Peng Du; Wen-Sheng Rao; Dao-Zhen Jiang; Wei Zhang; Ming Qiu
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.